Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Trainor

Showing results (91-100 of 104) with videos related to

Pageof 11
Sort By:
The Journal of Pharmacology and Experimental Therapeutics|January 27, 2004
Anxiolytic-like effects of the corticotropin-releasing factor1 (CRF1) antagonist DMP904 [4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine] administered acutely or chronically at doses occupying central CRF1 receptors in ratsSnjezana Lelas, Harvey Wong, Yu-Wen Li, et al.
The New England Journal of Medicine|June 14, 2018
Clinical Trial of Fluid Infusion Rates for Pediatric Diabetic KetoacidosisNathan Kuppermann, Simona Ghetti, Jeff E Schunk, et al.
Journal of Medicinal Chemistry|November 13, 2004
Synthesis and biological evaluation of 1-aryl-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-4-one inhibitors of cyclin-dependent kinasesJay A Markwalder, Marc R Arnone, Pamela A Benfield, et al.
Bioorganic & Medicinal Chemistry Letters|June 18, 2002
CCR3 antagonists: a potential new therapy for the treatment of asthma. Discovery and structure-activity relationshipsDean A Wacker, Joseph B Santella, Daniel S Gardner, et al.
ACS Medicinal Chemistry Letters|January 29, 2016
Discovery of the Selective CYP17A1 Lyase Inhibitor BMS-351 for the Treatment of Prostate CancerAudris Huang, Lata Jayaraman, Aberra Fura, et al.
Journal of Medicinal Chemistry|August 12, 2008
Discovery of pyrrolopyridine-pyridone based inhibitors of Met kinase: synthesis, X-ray crystallographic analysis, and biological activitiesKyoung Soon Kim, Liping Zhang, Robert Schmidt, et al.
Bioorganic & Medicinal Chemistry Letters|February 2, 2011
Pyrrolo[1,2-f]triazines as JAK2 inhibitors: achieving potency and selectivity for JAK2 over JAK3Lalgudi S Harikrishnan, Muthoni G Kamau, Honghe Wan, et al.
Molecular Cancer Therapeutics|May 18, 2005
Matrix metalloproteinase-activated doxorubicin prodrugs inhibit HT1080 xenograft growth better than doxorubicin with less toxicityCharles F Albright, Nilsa Graciani, Wei Han, et al.
Journal of Medicinal Chemistry|March 18, 2005
Discovery of CC chemokine receptor-3 (CCR3) antagonists with picomolar potencyGeorge V De Lucca, Ui Tae Kim, Brian J Vargo, et al.
Bioorganic & Medicinal Chemistry Letters|October 7, 2011
Synthesis and in vivo evaluation of cyclic diaminopropane BACE-1 inhibitorsLorin A Thompson, Jianliang Shi, Carl P Decicco, et al.
Pageof 11

Showing results (91-100 of 104) with videos related to

Sort By:
Pageof 11
The Journal of Pharmacology and Experimental Therapeutics|January 27, 2004
Anxiolytic-like effects of the corticotropin-releasing factor1 (CRF1) antagonist DMP904 [4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine] administered acutely or chronically at doses occupying central CRF1 receptors in ratsSnjezana Lelas, Harvey Wong, Yu-Wen Li, et al.
The New England Journal of Medicine|June 14, 2018
Clinical Trial of Fluid Infusion Rates for Pediatric Diabetic KetoacidosisNathan Kuppermann, Simona Ghetti, Jeff E Schunk, et al.
Journal of Medicinal Chemistry|November 13, 2004
Synthesis and biological evaluation of 1-aryl-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-4-one inhibitors of cyclin-dependent kinasesJay A Markwalder, Marc R Arnone, Pamela A Benfield, et al.
Bioorganic & Medicinal Chemistry Letters|June 18, 2002
CCR3 antagonists: a potential new therapy for the treatment of asthma. Discovery and structure-activity relationshipsDean A Wacker, Joseph B Santella, Daniel S Gardner, et al.
ACS Medicinal Chemistry Letters|January 29, 2016
Discovery of the Selective CYP17A1 Lyase Inhibitor BMS-351 for the Treatment of Prostate CancerAudris Huang, Lata Jayaraman, Aberra Fura, et al.
Journal of Medicinal Chemistry|August 12, 2008
Discovery of pyrrolopyridine-pyridone based inhibitors of Met kinase: synthesis, X-ray crystallographic analysis, and biological activitiesKyoung Soon Kim, Liping Zhang, Robert Schmidt, et al.
Bioorganic & Medicinal Chemistry Letters|February 2, 2011
Pyrrolo[1,2-f]triazines as JAK2 inhibitors: achieving potency and selectivity for JAK2 over JAK3Lalgudi S Harikrishnan, Muthoni G Kamau, Honghe Wan, et al.
Molecular Cancer Therapeutics|May 18, 2005
Matrix metalloproteinase-activated doxorubicin prodrugs inhibit HT1080 xenograft growth better than doxorubicin with less toxicityCharles F Albright, Nilsa Graciani, Wei Han, et al.
Journal of Medicinal Chemistry|March 18, 2005
Discovery of CC chemokine receptor-3 (CCR3) antagonists with picomolar potencyGeorge V De Lucca, Ui Tae Kim, Brian J Vargo, et al.
Bioorganic & Medicinal Chemistry Letters|October 7, 2011
Synthesis and in vivo evaluation of cyclic diaminopropane BACE-1 inhibitorsLorin A Thompson, Jianliang Shi, Carl P Decicco, et al.
Pageof 11